Incheon, South Korea

Eunhwa Ko

This inventor holds 4 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignees: Voronoi Inc., Dana-Farber-Cancer Institute Inc., Daegu-Gyeongbuk Medical Innovation Foundation. Active years: 2025-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Eunhwa Ko. Retrieved from https://idiyas.com/inventor/eunhwa-ko-fsugt0ds

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 4 

% Patents Active = 50.0

 

Average Co-Inventor Count = 9.4

ph-index = 1


Company Filing History:


Years Active: 2025-2026

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Eunhwa Ko: Innovator in Neurodegenerative Disease Treatment

Introduction

Eunhwa Ko is a prominent inventor based in Incheon, South Korea, recognized for her contributions to the field of pharmaceuticals and innovative treatments for neurodegenerative diseases. With a focus on compounds that target LRRK2, her groundbreaking research holds the potential for developing therapies for conditions such as Parkinson's disease and brain cancers.

Latest Patents

Eunhwa Ko holds one significant patent titled "Azaindole inhibitors of wild-type and mutant forms of LRRK2." This patent discloses compounds with inhibitory activity against LRRK2, alongside pharmaceutical compositions containing these compounds. The methods of utilizing these compounds aim to treat various diseases, particularly neurodegenerative disorders and brain cancers, including gliomas and glioblastomas.

Career Highlights

Throughout her career, Eunhwa Ko has had the opportunity to work at esteemed institutions, including the Dana-Farber Cancer Institute and Voronoi, Inc. Her experience in these environments has enhanced her expertise in drug development and research.

Collaborations

Eunhwa Ko has collaborated with notable colleagues such as Nathanael Schiander Gray and John M. Hatcher. These partnerships have been essential in advancing her research and broadening the impact of her discoveries in the scientific community.

Conclusion

Eunhwa Ko's innovative approaches and her patent on LRRK2 inhibitors stand as a testament to her commitment to enhancing treatment options for neurodegenerative disorders. Her contributions not only pave the way for potential new therapies but also highlight the importance of collaboration in the field of medical research.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…